I Braunstein1, R Klein, J Okawa, V P Werth. 1. Dermatology Section, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA.
Abstract
BACKGROUND: There is increased expression of type I interferon (IFN)-regulated proteins in the blood and target tissues of patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). Patients with SLE have increased IFN-regulated gene expression pointing towards a possible underlying genetic defect. OBJECTIVES: To determine expression levels of five type I IFN-regulated genes that are highly expressed in SLE in the peripheral blood of patients with CLE and to correlate the expression levels with cutaneous disease activity. METHODS: Peripheral blood was obtained from 10 healthy controls and 30 patients with CLE, including eight with concomitant SLE. Total RNA was extracted and reverse transcribed into complementary DNA. Gene expression levels were measured by real-time polymerase chain reaction. Gene expression was normalized to GAPDH, standardized to healthy controls and then summed to calculate an IFN score for each patient. Disease activity was assessed with the Cutaneous Lupus Area and Severity Index (CLASI). RESULTS: Patients with subacute CLE (SCLE) and discoid lupus erythematosus (DLE) had elevated IFN scores compared with healthy controls regardless of concomitant SLE (P < 0·01 with SLE and P < 0·05 without SLE). There was no difference between patients with tumid lupus erythematosus (TLE) and healthy controls. The IFN score correlated with CLASI scores (Spearman's rho = 0·55, P = 0·0017). CONCLUSIONS: Patients with SCLE and DLE have an IFN signature, as seen in SLE. The level of gene expression correlates with cutaneous disease activity. These findings support a shared pathogenesis between SLE and some subtypes of CLE.
BACKGROUND: There is increased expression of type I interferon (IFN)-regulated proteins in the blood and target tissues of patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). Patients with SLE have increased IFN-regulated gene expression pointing towards a possible underlying genetic defect. OBJECTIVES: To determine expression levels of five type I IFN-regulated genes that are highly expressed in SLE in the peripheral blood of patients with CLE and to correlate the expression levels with cutaneous disease activity. METHODS: Peripheral blood was obtained from 10 healthy controls and 30 patients with CLE, including eight with concomitant SLE. Total RNA was extracted and reverse transcribed into complementary DNA. Gene expression levels were measured by real-time polymerase chain reaction. Gene expression was normalized to GAPDH, standardized to healthy controls and then summed to calculate an IFN score for each patient. Disease activity was assessed with the Cutaneous Lupus Area and Severity Index (CLASI). RESULTS:Patients with subacute CLE (SCLE) and discoid lupus erythematosus (DLE) had elevated IFN scores compared with healthy controls regardless of concomitant SLE (P < 0·01 with SLE and P < 0·05 without SLE). There was no difference between patients with tumid lupus erythematosus (TLE) and healthy controls. The IFN score correlated with CLASI scores (Spearman's rho = 0·55, P = 0·0017). CONCLUSIONS:Patients with SCLE and DLE have an IFN signature, as seen in SLE. The level of gene expression correlates with cutaneous disease activity. These findings support a shared pathogenesis between SLE and some subtypes of CLE.
Authors: Xuebing Feng; Hui Wu; Jennifer M Grossman; Punchong Hanvivadhanakul; John D FitzGerald; Grace S Park; Xin Dong; Weiling Chen; Michelle H Kim; Haoling H Weng; Daniel E Furst; Alan Gorn; Maureen McMahon; Mihaela Taylor; Ernest Brahn; Bevra H Hahn; Betty P Tsao Journal: Arthritis Rheum Date: 2006-09
Authors: Joerg Albrecht; Lynne Taylor; Jesse A Berlin; Samuel Dulay; Gina Ang; Steven Fakharzadeh; Jonathan Kantor; Ellen Kim; Giuseppe Militello; Karen McGinnis; Stephen Richardson; James Treat; Carmela Vittorio; Abby Van Voorhees; Victoria P Werth Journal: J Invest Dermatol Date: 2005-11 Impact factor: 8.551
Authors: Stephan Meller; Franziska Winterberg; Michel Gilliet; Anja Müller; Ingrida Lauceviciute; Juliane Rieker; Norbert J Neumann; Robert Kubitza; Michael Gombert; Erich Bünemann; Ulrike Wiesner; Petra Franken-Kunkel; Holger Kanzler; Marie-Caroline Dieu-Nosjean; Ali Amara; Thomas Ruzicka; Percy Lehmann; Albert Zlotnik; Bernhard Homey Journal: Arthritis Rheum Date: 2005-05
Authors: Gillian Rice; William G Newman; John Dean; Teresa Patrick; Rekha Parmar; Kim Flintoff; Peter Robins; Scott Harvey; Thomas Hollis; Ann O'Hara; Ariane L Herrick; Andrew P Bowden; Fred W Perrino; Tomas Lindahl; Deborah E Barnes; Yanick J Crow Journal: Am J Hum Genet Date: 2007-02-19 Impact factor: 11.025
Authors: Macrene R Alexiades-Armenakas; Marisa Baldassano; Benji Bince; Victoria Werth; Jean-Claude Bystryn; Hideko Kamino; Nicholas A Soter; Andrew G Franks Journal: Arthritis Rheum Date: 2003-08-15
Authors: C Landolt-Marticorena; G Bonventi; A Lubovich; C Ferguson; T Unnithan; J Su; D D Gladman; M Urowitz; P R Fortin; J Wither Journal: Ann Rheum Dis Date: 2008-09-04 Impact factor: 19.103
Authors: Johann E Gudjonsson; J Michelle Kahlenberg; Mrinal K Sarkar; Grace A Hile; Lam C Tsoi; Xianying Xing; Jianhua Liu; Yun Liang; Celine C Berthier; William R Swindell; Matthew T Patrick; Shuai Shao; Pei-Suen Tsou; Ranjitha Uppala; Maria A Beamer; Anshika Srivastava; Stephanie L Bielas; Paul W Harms; Spiro Getsios; James T Elder; John J Voorhees Journal: Ann Rheum Dis Date: 2018-07-18 Impact factor: 19.103
Authors: J S Lehman; S Dasari; S S Damodaran; R A El-Azhary; L E Gibson; S K Hashmi; W J Hogan; S J Kenderian; M S Patnaik; M R Litzow; H M Lazarus; A Meves Journal: Clin Exp Dermatol Date: 2018-10-02 Impact factor: 3.470
Authors: Jason S Knight; Venkataraman Subramanian; Alexander A O'Dell; Srilakshmi Yalavarthi; Wenpu Zhao; Carolyne K Smith; Jeffrey B Hodgin; Paul R Thompson; Mariana J Kaplan Journal: Ann Rheum Dis Date: 2014-08-07 Impact factor: 19.103